Could cannabinoid biosynthesis be the next big thing for investors?

Could cannabinoid biosynthesis be the next big thing for investors?

Legalisation, increasing acceptance of and growing demand for pharmaceutical and consumer products mean the cannabinoids industry is booming. Will biosynthesis take it to new heights?

Writer and journalist Vivienne Parry speaks to Randy Baron of Pinnacle Associates, Roy Lipski of Creo, Trevor Peters of Willow Biosciences and Nick Davis of Memery Crystal as they discuss the opportunity for investors and how biosynthesis will affect the direction of cannabinoids.

This is the cannabinoids conversation you won’t want to miss.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.